Xencor, Inc. (XNCR)
NASDAQ: XNCR · Real-Time Price · USD
13.18
+0.73 (5.86%)
Apr 24, 2026, 1:09 PM EDT - Market open
Xencor Employees
Xencor had 260 employees as of December 31, 2025. The number of employees increased by 10 or 4.00% compared to the previous year.
Employees
260
Change (1Y)
10
Growth (1Y)
4.00%
Revenue / Employee
$482,985
Profits / Employee
-$353,550
Market Cap
966.53M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 260 | 10 | 4.00% | 260 | 0 |
| Dec 31, 2024 | 250 | -30 | -10.71% | 250 | 0 |
| Dec 31, 2023 | 280 | -1 | -0.36% | 280 | 0 |
| Dec 31, 2022 | 281 | 27 | 10.63% | 281 | 0 |
| Dec 31, 2021 | 254 | 52 | 25.74% | 254 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,300 |
| Maravai LifeSciences Holdings | 435 |
| Geron | 258 |
| Sana Biotechnology | 142 |
| Janux Therapeutics | 109 |
| CytomX Therapeutics | 69 |
| Alto Neuroscience | 68 |
| Compass Therapeutics | 39 |
XNCR News
- 7 weeks ago - Xencor Announces Change to Ultomiris® Royalty Revenue Forecast - Business Wire
- 2 months ago - Xencor Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 2 months ago - Xencor to Participate at Upcoming Investor Conferences - Business Wire
- 3 months ago - Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones - Business Wire
- 4 months ago - Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies - Business Wire
- 6 months ago - Xencor Reports Third Quarter 2025 Financial Results - Business Wire
- 6 months ago - Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma - Business Wire
- 6 months ago - Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma - Business Wire